Treatment of CML in pediatric patients: should imatinib mesylate (STI-571, Gleevec) or allogeneic hematopoietic cell transplant be front-line therapy?

Pediatric Blood & Cancer
Michael A Pulsipher

Abstract

Long-term survival of pediatric patients with chronic myelogenous leukemia (CML) receiving myeloablative hematopoietic stem cell transplantation from fully-matched related and unrelated donors has been reported between 60 and 75%, but is associated with significant morbidity. Imatinib mesylate (STI-571, Gleevec) and reduced intensity conditioning stem cell transplantation (RIC) are two promising new tools that offer potential for decreasing therapy associated morbidity for patients with CML. Large trials have shown significant responses in chronic phase patients treated with imatinib and reasonable but short-lived responses in advanced phase CML. Data from adult studies is beginning to define populations likely to progress or have prolonged responses to imatinib, and some adult treatment paradigms are moving toward reserving transplantation until patients are at risk of failure with imatinib. Early trials of RIC transplantation in CML show decreased transplant related morbidity with efficacy similar to conventional transplantation, but the approach has yet to be verified in phase III studies. Data in pediatric patients with imatinib and RIC transplantation is limited. Studies with imatinib are underway in pediatrics, but whethe...Continue Reading

References

May 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A S GamisN K Ramsay
Apr 2, 1998·The New England Journal of Medicine·J A HansenC Anasetti
Aug 28, 1999·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·D L PorterJ H Antin
Dec 14, 1999·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·D E GladstoneR J Jones
Jan 5, 2000·The Journal of Clinical Investigation·B J Druker, N B Lydon
Nov 28, 2001·Hematology·B J DrukerJ M Goldman
Jan 5, 2002·Hematology/oncology Clinics of North America·M A Pulsipher, A Woolfrey
Feb 28, 2002·Blood·Michele BaccaraniUNKNOWN Italian Cooperative Study Group on Myeloid Leukemia
Mar 1, 2002·The New England Journal of Medicine·Hagop KantarjianUNKNOWN International STI571 CML Study Group
Mar 21, 2002·Journal of Pediatric Hematology/oncology·Frédéric MillotFrançois Guilhot
Mar 29, 2002·The Hematology Journal : the Official Journal of the European Haematology Association·C PocockJ Goldman
May 7, 2002·Journal of Pediatric Hematology/oncology·Anjali SharathkumarJohn Doyle
Nov 26, 2002·Hematology·Brian J DrukerJerald Radich
Mar 15, 2003·The New England Journal of Medicine·Stephen G O'BrienUNKNOWN IRIS Investigators
Apr 26, 2003·Blood·Kate CwynarskiUNKNOWN Paediatric and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation
Sep 13, 2003·Leukemia·E OlavarriaUNKNOWN Chronic Leukaemia Working Party of the European Group of Bone and Marrow Transplantation (EBMT)
Oct 10, 2003·The New England Journal of Medicine·Tim P HughesUNKNOWN International Randomised Study of Interferon versus STI571 (IRIS) Study Group
Nov 25, 2003·Hematology·Junia V MeloJane F Apperley

❮ Previous
Next ❯

Citations

Jan 8, 2008·Bone Marrow Transplantation·S Shenoy, F O Smith
Aug 23, 2011·Pediatric Clinics of North America·Brian P Kurtz, Annah N Abrams
May 19, 2010·Child and Adolescent Psychiatric Clinics of North America·Brian P Kurtz, Annah N Abrams
Mar 24, 2010·Pediatric Clinics of North America·Alan S WayneR Maarten Egeler
Mar 17, 2010·Cancer Treatment Reviews·C Michel ZwaanUNKNOWN 'innovative therapies for children with cancer' European consortium
Feb 5, 2008·Pediatric Clinics of North America·Rupert HandgretingerR Maarten Egeler
Jul 22, 2009·Pediatric Blood & Cancer·Michael J BurkeRichard Kadota
Mar 12, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Sonali ChaudhuryWael Saber
Feb 24, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Justin N BakerJavier R Kane
Apr 17, 2010·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·G A P OliveiraJ L Silva

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.